Cargando…

Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients

Dysregulation of long non-coding RNA zinc finger antisense 1 (ZFAS1) has been reported in many types of cancers. We performed a synthetic analysis to clarify its prognostic significance as a cancer molecular-marker. Several databases (including PubMed, Web of Science, Embase together with Wanfang an...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Fangteng, Gao, Hui, Li, Siyu, Ni, Xiaolin, Zhu, Zhengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617445/
https://www.ncbi.nlm.nih.gov/pubmed/28977885
http://dx.doi.org/10.18632/oncotarget.18633
_version_ 1783266987293540352
author Liu, Fangteng
Gao, Hui
Li, Siyu
Ni, Xiaolin
Zhu, Zhengming
author_facet Liu, Fangteng
Gao, Hui
Li, Siyu
Ni, Xiaolin
Zhu, Zhengming
author_sort Liu, Fangteng
collection PubMed
description Dysregulation of long non-coding RNA zinc finger antisense 1 (ZFAS1) has been reported in many types of cancers. We performed a synthetic analysis to clarify its prognostic significance as a cancer molecular-marker. Several databases (including PubMed, Web of Science, Embase together with Wanfang and China National Knowledge Internet database) were retrieved to identify ZFAS1-related articles. A total of eight articles were included in this meta-analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were applied to assess the association between ZFAS1 expression level and overall survival (OS). Odds ratios (OR) were calculated with RevMan 5.3 software to determine the relationship between ZFAS1 expression and clinicopathologic features. The pooled results of the meta-analysis indicated that high ZFAS1 expression level was positively correlated with poor OS (HR = 1.87, 95% CI: 1.38-2.36, p< 0.001) in human solid cancers. The statistical significance was also observed in subgroup analysis stratified by the cancer type, analysis method, sample size and follow-up time. Furthermore, the elevated ZFAS1 expression was significantly related to positive lymph node metastasis (OR = 4.18, 95% CI: 2.70-6.48, p< 0.001). The present results suggest that ZFAS1 might be served as a novel promising biomarker for prognosis in Chinese patients with solid cancers.
format Online
Article
Text
id pubmed-5617445
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56174452017-10-03 Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients Liu, Fangteng Gao, Hui Li, Siyu Ni, Xiaolin Zhu, Zhengming Oncotarget Research Paper Dysregulation of long non-coding RNA zinc finger antisense 1 (ZFAS1) has been reported in many types of cancers. We performed a synthetic analysis to clarify its prognostic significance as a cancer molecular-marker. Several databases (including PubMed, Web of Science, Embase together with Wanfang and China National Knowledge Internet database) were retrieved to identify ZFAS1-related articles. A total of eight articles were included in this meta-analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were applied to assess the association between ZFAS1 expression level and overall survival (OS). Odds ratios (OR) were calculated with RevMan 5.3 software to determine the relationship between ZFAS1 expression and clinicopathologic features. The pooled results of the meta-analysis indicated that high ZFAS1 expression level was positively correlated with poor OS (HR = 1.87, 95% CI: 1.38-2.36, p< 0.001) in human solid cancers. The statistical significance was also observed in subgroup analysis stratified by the cancer type, analysis method, sample size and follow-up time. Furthermore, the elevated ZFAS1 expression was significantly related to positive lymph node metastasis (OR = 4.18, 95% CI: 2.70-6.48, p< 0.001). The present results suggest that ZFAS1 might be served as a novel promising biomarker for prognosis in Chinese patients with solid cancers. Impact Journals LLC 2017-06-27 /pmc/articles/PMC5617445/ /pubmed/28977885 http://dx.doi.org/10.18632/oncotarget.18633 Text en Copyright: © 2017 Liu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Liu, Fangteng
Gao, Hui
Li, Siyu
Ni, Xiaolin
Zhu, Zhengming
Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients
title Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients
title_full Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients
title_fullStr Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients
title_full_unstemmed Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients
title_short Long non-coding RNA ZFAS1 correlates with clinical progression and prognosis in cancer patients
title_sort long non-coding rna zfas1 correlates with clinical progression and prognosis in cancer patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617445/
https://www.ncbi.nlm.nih.gov/pubmed/28977885
http://dx.doi.org/10.18632/oncotarget.18633
work_keys_str_mv AT liufangteng longnoncodingrnazfas1correlateswithclinicalprogressionandprognosisincancerpatients
AT gaohui longnoncodingrnazfas1correlateswithclinicalprogressionandprognosisincancerpatients
AT lisiyu longnoncodingrnazfas1correlateswithclinicalprogressionandprognosisincancerpatients
AT nixiaolin longnoncodingrnazfas1correlateswithclinicalprogressionandprognosisincancerpatients
AT zhuzhengming longnoncodingrnazfas1correlateswithclinicalprogressionandprognosisincancerpatients